Trial Profile
EsPhALL 2004 An Open-label, Randomized Phase II/III Study to Compare the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL) - EsPhALL 2004
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms EsPhALL 2004
- 15 Sep 2016 New trial record